Cancer Epigenetics Journal (CE)’s Editorial Board has been selected with three criteria in mind: i. each CEJ Editorial Board Member is a leading (if not the leading) scientist in her/his field; ii. each CEJ Editorial Board Member upholds the highest standards of scientific rigor and ethics; and iii. each Editorial Board Member is committed to advancing science and to the betterment of research practices, in a spirit of collaboration, knowledge sharing, and collegiality. These criteria help ensure that all papers submitted to CEJ are fairly evaluated by the experts of the field, and that are all papers selected for publication significantly advance the field.
Editors-in-Chief
Sharon Dent 
Dr. Sharon Y.R. Dent is Professor at University of Texas MD Anderson Cancer Center and holds the Department of Epigenetics & Molecular Carcinogenesis J. Ralph Meadows Chair. She is also Director of the Virginia Harris Cockrell Cancer Research Center at Science Park in Smithville, TX, and Director of the Center for Cancer Epigenetics at University of Texas MD Anderson Cancer Center (Houston, TX, USA). She is an expert of histone acetyltransferases (HATs) and development, as well as in the crosstalk and cross-regulation of histone PTMs in normal and cancer cells. Dr. Dent is also Editor of Molecular Cell (Cell Press).
Peter Jones
Dr. Peter Jones is a world renown DNA methylation expert and former President of the American Association for Cancer Research (AACR). Dr. Jones is a Distinguished Professor, Director of the Center for Epigenetics, and Chief Scientific Officer of Van Andel Research Institute (Grand Rapids, MI, USA). He is co-founder of Stand Up To Cancer (SU2C) Epigenetics Dream Team, and is on the scientific advisory boards of Cancer Research UK Cambridge Institute, and of Blueprint, a large-scale epigenome project gathering 42 European universities and research institutes. Dr. Jones is a member of the National Academy of Sciences, USA.
Editorial Board
Cheryl Arrowsmith
Dr. Cheryl Arrowsmith is Professor of Medical Biophysics at the University of Toronto and Senior Scientist at the Princess Margaret Cancer Centre (Toronto, Canada). She is also Structural Genomics Consortium Chief (SGC-Toronto) and holds the Canada Research Chair in Structural Genomics. Dr. Arrowsmith is also Founder of Affinium Pharmaceuticals and is on the Board of Directors of Academic Drug Discovery Consortium. In addition to the Cancer Epigenetics journal series, Dr. Arrowsmith is Editor of Cell Chemical Biology (Cell Press).
Stephen Baylin
Dr. Stephen B. Baylin is Professor of Medicine, Professor of Oncology, and the Virginia and D.K. Ludwig Professor for Cancer Research at Johns Hopkins University (Baltimore, MD, USA). Dr. Baylin is also Chief of the Cancer Biology Division of the Johns Hopkins Oncology Center and Associate Director for Research Programs of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Together with Peter Jones, Dr. Baylin leads the national Stand up to Cancer (SU2C) team, served on the AACR Board of Directors, and is an Officer of the Cancer Epigenetics Society. Dr. Baylin was elected in 2017 to the National Academy of Sciences, USA.
Stephan Beck
Dr. Stephan Beck is Professor of Medical Genomics at University College London (UCL) Cancer Institute (London, UK). Dr. Beck headed the human genome sequencing project at the Wellcome Trust Sanger Institute, co-founded the Human Epigenome Project, and co-authored the paper reporting the initial human genome sequence cited more than 20,000 times. Dr. Beck is also leading the British Personal Genome Project (PGP-UK), which aims at recruiting 100,000 people for the first open-access database combining both DNA and health data, thus allowing researchers to link gene variants to specific conditions. Dr. Beck is also a member of faculty of 1000 (f1000) and a Fellow of the Academy of Medical Sciences.
Giacomo Cavalli
Dr. Giacomo Cavalli is Head of the Chromatin and Cell Biology Laboratory at the Institute for Human Genetics (Montpellier, France). Together with Renato Paro, Dr. Cavalli was first to show transgenerational inheritance of chromatin states in metazoans. He is a Polycomb and Trithorax group of proteins expert, and first to demonstrate PcG tumor suppressive function in Drosophila. Dr. Cavalli is also a Permanent Member of the EpigeneSys Network of Excellence, of the Laboratory of Excellence EpiGenMed, and a Senior Member of the Cancer Epigenetics Society.
Susan Clark
Dr. Susan J. Clark is Head of the laboratory for Epigenetics Research, of the Genomics and Epigenetics Division and of the Cancer Epigenetics Program at the Garvan Institute of Medical Research, and of the Cancer Research Division at the Kinghorn Cancer Centre, and Professor at Univ. of New South Wales Faculty of Medicine (Sydney, Australia). Dr. Clark is also Founding Member of the International Human Epigenome Consortium, President of the Australian Epigenetics Alliance, a Fellow of the Australian Academy of Science, and an Officer of the Cancer Epigenetics Society.
Luciano Di Croce
Dr. Luciano Di Croce heads the Epigenetics Events in Cancer Group at the Centre for Genomic Regulation (CGR), an international biomedical research institute of excellence (Barcelona, Spain). Dr. Di Croce’s expertise lays in the epigenetic mechanisms of leukemia and is Professor at the Catalan Institute of Research and Advanced Studies (ICREA), an Associate Member of the EpigeneSys Network of Excellence, and an Elected Member of the European Molecular Biology Organization (EMBO). Dr. Di Croce is also Editor of Molecular and Cellular Biology (ASM) and of Science Advances (AAAS).
Lucy Godley
Dr. Lucy A. Godley is Professor at the Department of Medicine, Section of Hematology/Oncology at University of Chicago (Chicago, IL, USA). Dr. Godley is an expert in the role of DNMT3B and of DNA methylation and hydroxymethylation in hematological malignancies. She made several seminal contributions to the field, including the role of IDH1 and IDH2 mutations and of TET2 in myeloid transformation. Dr. Godley was inducted into the American Society of Clinical Investigation, is Editor of Clinical Cancer Research (AACR press), and is Editor of Blood (ASH press).
Cigall Kadoch
Dr. Cigall Kadoch is Ass. Professor of Pediatric Oncology at the Dana-Farber Cancer Institute, Ass. Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and Member at the Center for the Science of Therapeutics at the Broad Institute of MIT and Harvard University. Dr. Kadoch is an expert of the Swi/Snf chromatin remodeling machineries, particularly of the BAF complex role in chromatin biology and oncogenic pathways. Dr. Kadoch has received several accolades including being selected by the 35 MIT Innovators Under 35, and the Forbes list of 30 Under 30.
Tatiana Kutateladze
Dr. Tatiana Kutateladze is a Faculty Member of the Program in Structural Biology and Biochemistry, the Neuroscience Program, the Biomedical Sciences Program, the Medical Scientist Training Program, the Molecular Biology Program, and of University of Colorado Cancer Center, and is Professor of Pharmacology at University of Colorado Anschutz Medical Campus (Aurora, CO, USA). Dr. Kutateladze has unraveled many structural determinants of the cancer epigenetic network & elucidated the molecular mechanisms of methyllysine & acyllysine recognition by epigenetic readers.
Jonathan Licht
Dr. Jonathan D. Licht is Director of University of Florida Health Cancer Center (Gainesville, FL, USA), and holds the Marshall E. Rinker Sr. Foundation and David B and Leighan R. Rinker Chair. Dr. Licht is also an NCI-funded Chicago Physical Sciences Oncology Center co-leader, and is a cancer epigenetics Principal Investigator of a Leukemia and Lymphoma Society Specialized Center and a Multiple Myeloma Research Foundation program. In addition to Cancer Epigenetics journal series, Dr. Licht is also Editor of Cancer Cell (Cell Press).
Ana Pombo
Dr. Ana Pombo is Group leader at Berlin Institute for Medical Systems Biology, the Max Delbrück Center, Professor at Humboldt University (Berlin, Germany), and Member of the Epigenome Network of Excellence. Prior to her current position, Dr. Pombo led research at the Imperial College London / Medical Research Council (MRC) in London, UK. Dr. Pombo is an expert in three-dimensional chromatin folding, long-range enhancer-promoter communication, gene priming and transcriptional activation, and stem cells epigenetics in normal development and disease states. Dr. Pombo is Editor of Molecular and Cellular Biology (ASM) and of Journal of Cell Biology (Rockefeller University Press).
Keith Robertson
Dr. Keith D. Robertson is the Professor of Molecular Pharmacology & Experimental Therapeutics and Head of the Epigenetic Etiology of Human Disease Laboratory at Mayo Clinic (Rochester, MN, USA). Dr. Robertson was also a Georgia Cancer Coalition Distinguished Cancer Scholar, President of the Epigenetics Society, and is the Vice-President of the Cancer Epigenetics Society. Other academic accomplishments include Faculty positions at the NCI/NIH, and the Department of Biochemistry and Molecular Biology and Shands Cancer Center at University of Florida.
Raul Urrutia
Dr. Raul Urrutia is Professor of Medicine, Professor of Biochemistry and Molecular Biology, and Professor of Biophysics at the Mayo Clinic (Rochester, MN, USA). Dr. Urrutia serves as the Director of Epigenomics Education and of Academic Relationships, Consultant for the Division of Gastroenterology and Hepatology, Consultant for the Department of Physiology and Biomedical Engineering, and Member of the Diagnostic Odyssey Functional Validation Program at Mayo’s Center for Individualized Medicine. Dr. Urrutia is also Director of the GI Unit, Director of the PhD Program in Tumor Biology, Associate Director for Genomics at the Mayo Clinic General Clinical Research Center, and Editor of Journal of Biological Chemistry (ASBMB).
Jerry Workman
Dr. Jerry Workman is an Investigator at the Stowers Institute for Medical Research (Kansas City, MO, USA). Prior, Dr. Workman was a Fellow at Harvard University School of Medicine and the Massachusetts General Hospital (MGH), a Howard Hughes Medical Institute (HHMI) Investigator, and a Scientific Board Counselor of the National Cancer Institute (NIH/NCI). Dr. Workman is widely recognized for his research on HATs, notably for his discovery of the Tip60 and SAGA complexes. Dr. Workman also served as Editor of Molecular and Cellular Biology and is currently Editor of EMBO Reports and of eLife. Dr. Workman was inducted into the American Academy of Arts and Sciences in 2013.